Effects of Coenzyme Q10 in PSP and CBD

• Status: Completed
• Trial end date: 2005-09-01
• Target enrollment: 0
• Participant gender: All

Summary

To compare the efficacy, safety and tolerability of Coenzyme Q 10 versus placebo in patients with atypical parkinsonian syndromes corticobasal degeneration (CBD) and progressive supranuclear palsy (PSP) ).

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Lahey Clinic
• Treatments: Coenzyme Q10; Ubiquinone

Criteria

Inclusion Criteria:

• Patients fulfilling the diagnostic criteria of PSP and CBD (above) and who were diagnosed within the past 5 years

• Age > 40

• Subjects receiving anticholinergics, amantadine, dopamine agonists, carbidopa/levodopa, eldepryl, or comtan must be on a stable dose for at least 30 days prior to baseline visit.

• Patients agreeable to participate in the study.

Exclusion Criteria:

• Prior or concurrent therapy with anticholinergics, amantadine,a dopamine agonist,carbidopa/levodopa or comtan within 30 days of the baseline visit.

• Parkinsons disease or any other atypical parkinsonism; Parkinsonism due to drugs.

• History of pallidotomy, thalamotomy, deep brain stimulation or fetal tissue transplant.

• Previous use of coenzyme Q10 within 60 days of the baseline visit.